Oxidation-resistant ribonuclease inhibitor

• US 7,560,248 B1
• Filed: 01/20/1999
• Issued: 07/14/2009
• Est. Priority Date: 01/20/1999
• Status: Expired due to Fees

• Current Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Original Assignee: Wisconsin Alumni Research Foundation (University of Wisconsin System)
• Inventors: Raines, Ronald T.
• Primary Examiner(s): Hutson; Richard G
• Application Number:
  US09/234,028
• Time in Patent Office: 3,828 Days
• Field of Search: 435/185, 530/350, 536/23.5
• US Class Current: 435/69.2
• CPC Class Codes: C07K 14/4703 Inhibitors; Suppressors

Abstract

Mutant forms of ribonuclease inhibitor are described which are rendered more resistant to oxidation while retaining affinity for both ribonuclease and angiogenin. The mutant forms have another amino acid, typically an alanine, substituted for one or more of the adjacent cysteine residues in the wild-type sequence to prevent the formation of unwanted disulfide bonds which can disrupt the effectiveness of the molecule.

Claims

1. An oxidation-resistant engineered ribonuclease inhibitor (RI) selected from the group consisting of:

(i) a RI comprising the reference sequence of SEQ ID NO;

3, except for an alanine substitution of at least one cysteine residue at positions 95, 96, 329 and 330; and

(ii) a RI comprising the reference sequence of SEQ ID NO;

2, except for an alanine substitution of at least one cysteine residue at positions 324 and 325,

the RI having a greater resistance to oxidation relative to the reference sequence for the RI and retaining its specificity and binding affinity to ribonuclease.

2. The RI of claim 1, wherein the alanine substitution inhibits the formation of a disulfide bond with an adjacent cysteine residue.

3. The RI of claim 1, wherein the RI is 10 to 15 fold more resistant to oxidative damage than a RI comprising the relevant reference sequence.

4. The RI of claim 1, wherein the RI exhibits an in vitro inhibition of ribonucleolytic activity.

5. An oxidation-resistant ribonuclease inhibitor (RI) comprising the reference sequence of SEQ ID NO:

3, except for an alanine residue at one or more of positions 95, 96, 329 and 330.

6. The RI of claim 5, wherein the RI retains specificity and affinity of SEQ ID NO:

3 for binding to angiogenin.

7. The RI of claim 5, wherein the residues at positions 329 and 330 are alanine residues.

10. The RI of claim 5, wherein the residues at positions 95 and 96 are alanine residues.

11. The RI of claim 5, wherein the residues at positions 95, 96, 329 and 330 are alanine residues.

8. An oxidation-resistant ribonuclease inhibitor (RI) comprising the reference sequence of SEQ ID NO:

2, except for an alanine residue at one or both of positions 324 and 325.

9. The RI of claim 8, wherein the residues at positions 324 and 325 are alanine residues.